newsfilter
← Latest News
GlobeNewswire·

MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

EscharEx® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027 First quarter revenue of $1.5 million; full-year 2026 revenue guidance